Kymos Workshop at Farmaforum: Recent trends in the impurity profile of pharmaceuticals

Come to our workshop and learn more about impurity testing. Learn from firsthand experience. Our experts present real case studies from their daily work. Agenda: The challenge of Impurities in Pharmaceuticals. Jaume Pascual - Quality Director Case studies:           2.1.    Elemental Impurities: Control strategy in routine analysis and regulatory news. Gemma (...)

Read more

By |2022-08-04T14:58:40+02:00August 4th, 2022|News|Comments Off on Kymos Workshop at Farmaforum: Recent trends in the impurity profile of pharmaceuticals

Elemental Impurities: New regulations for human and veterinary pharmaceuticals and cosmetic products

Elemental impurities in pharmaceutical but also cosmetic products are increasingly receiving the attention of the authorities. New limits are being defined constantly and it is essential to always be up to date with the latest regulations. Gemma Solsona, Head of Department for Elemental Impurities, informs about the most important recent regulatory developments: “Currently, several changes (...)

Read more

By |2022-08-01T14:27:52+02:00July 25th, 2022|News|Comments Off on Elemental Impurities: New regulations for human and veterinary pharmaceuticals and cosmetic products

Bioequivalence studies in Europe

Bioequivalence studies are designed to show that two drugs are equivalent and substitutable. - But even though the medicines are replaceable, the providers of bioequivalence studies are not. Digna Tost, Department Manager of Bioanalysis of Small Molecules at Kymos, resumes why Kymos is the right partner for bioequivalence projects: "Our clients are looking for (...)

Read more

By |2022-06-28T14:32:30+02:00June 22nd, 2022|News|Comments Off on Bioequivalence studies in Europe

KYMOS SUPPORTS UKRAINIAN PEOPLE

From Kymos Group we have joined to the expressions of the international community condemning the military intervention of the Russian army against the Ukrainian population, as well as the demand for an end to the violence on Ukrainian territory, the escalation of the conflict and the recovery of the diplomatic channel and dialogue. Beyond words, (...)

Read more

By |2022-06-28T14:32:30+02:00June 14th, 2022|News|Comments Off on KYMOS SUPPORTS UKRAINIAN PEOPLE

Pharmaprogress – Bright lights are on the horizon

In 2023, Pharmaprogress will move into a more spacious, convenient, and state-of-the-art building in the Ancona area. Luca Gramaccioni, General Site Manager of Pharmaprogress, and his team are excited about having more room soon: "In 2001, Pharmaprogress was established in the current building. After 20 years the team increased from the original 6 to 26 (...)

Read more

By |2022-07-19T14:41:54+02:00May 24th, 2022|News|Comments Off on Pharmaprogress – Bright lights are on the horizon

Dissolution testing for all dosage forms

In recent months, we unfortunately had to turn down repeated requests for dissolution tests for which we would have needed the Dissolution USP 4 CE 7smart device. This was neither satisfactory for our customers nor for us. We have taken this situation seriously and ated accordingly: A brand-new Dissolution USP 4 CE 7smart device will (...)

Read more

By |2022-07-19T14:44:16+02:00May 10th, 2022|News|Comments Off on Dissolution testing for all dosage forms

Prolytic and Aeterna Zentaris – 20 years of improving human health together

For almost 20 years, Kymos’ German subsidiary Prolytic has accompanied Aeterna Zentaris in its development of pharmaceutical and diagnostic products. Katrin Dorfmeyer, Head of Chromatography, at Prolytic, and Dr. Michael Teifel, CSO at Aeterna Zentaris, shed light on the interesting project of the growth hormone secretagogue macimorelin (Macrilen, Ghryvelin) which they have been working on (...)

Read more

By |2022-07-19T15:01:35+02:00March 22nd, 2022|News|Comments Off on Prolytic and Aeterna Zentaris – 20 years of improving human health together

Joan Puig de Dou president of CataloniaBio & HealthTech

We congratulate our CEO Joan Puig de Dou on his election as president of CataloniaBio & HealthTech. We also send our congratulations to Mariona Serra-Pagès (GoodGut), Marta Palicio (Werfen OEM) and Isabel Amat Riera (Reig Jofre), and all other newly elected board members on their election to the CataloniaBio Board of Directors. We wish them (...)

Read more

By |2022-07-19T14:47:12+02:00March 3rd, 2022|News|Comments Off on Joan Puig de Dou president of CataloniaBio & HealthTech

Quantifying Active Enzymes – A bioanalytical challenge

Lisa Hentschel, Master of Molecular Biosciences, started her career at Prolytic eight years ago as a technician in the ELISA team. Since 2017, she now leads the Biology Department and is a recognized expert in large molecule bioanalysis, ADA determination and enzyme activity measurement. Together with Dr Busch, COO at Eleva, she shares her (...)

Read more

By |2022-07-21T13:35:08+02:00February 22nd, 2022|News|Comments Off on Quantifying Active Enzymes – A bioanalytical challenge

Nucleic Acids: From Biological Underdog to Biotech Top Dog

The bioanalysis of nucleic acids, especially in biological matrices, is one of the newest services offered by the Kymos Group and carried out at its German subsidiary Prolytic. Maria Fauth, Head of the Oligonucleotides Department, has dedicated her entire academic and corporate career to the research and analysis of nucleic acids. She and Dr. Janine (...)

Read more

By |2022-07-19T14:49:40+02:00February 3rd, 2022|News|Comments Off on Nucleic Acids: From Biological Underdog to Biotech Top Dog